T-Butylacetic Acid

T-Butylacetic Acid

SCHEMBL6098037

CC(C)(C)CC(=O)[O-].[Br-].[Zn+2]

nearest known ligand 0.42

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1

The experimentally established mechanism targets of T-Butylacetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CHRM1 known ✓ P11229 1/20 0.33
CA4 P22748 3/20 0.42
FFAR3 O14843 2/20 0.35
HDAC3 O15379 2/20 0.35
HDAC1 Q13547 2/20 0.35
HDAC2 Q92769 2/20 0.35
HDAC8 Q9BY41 2/20 0.35
HMGCR P04035 1/20 0.33
TBXA2R P21731 1/20 0.33
ADRA1A P35348 1/20 0.33
CYP2D6 P10635 1/20 0.32
TSHR P16473 1/20 0.32
CYP2C19 P33261 1/20 0.32
HIF1A Q16665 1/20 0.32
CA2 P00918 1/20 0.32
CASP1 P29466 1/20 0.32
CA1 P00915 4/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
T-Butylacetic Acid SCHEMBL973429 0.91
T-Butylacetic Acid SCHEMBL18258678 0.91 CA4 (0.43) CA4FFAR3HDAC3HDAC1HDAC2
T-Butylacetic Acid SCHEMBL6500330 0.91
T-Butylacetic Acid SCHEMBL11218671 0.91
T-Butylacetic Acid SCHEMBL4319302 0.91
T-Butylacetic Acid SCHEMBL3159252 0.88 CA4 (0.42) CA4FFAR3HDAC3HDAC1HDAC2
T-Butylacetic Acid SCHEMBL28123305 0.88 CA4 (0.42) CA4FFAR3HDAC3HDAC1HDAC2
T-Butylacetic Acid SCHEMBL28494927 0.86 CA4 (0.40) CA4FFAR3HDAC3HDAC1HDAC2
T-Butylacetic Acid SCHEMBL7859363 0.86 CA4 (0.40) CA4FFAR3HDAC3HDAC1HDAC2
T-Butylacetic Acid SCHEMBL6567111 0.81 CA4 (0.42) CA4FFAR3HDAC3HDAC1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7109352-B2 Process for producing optically active amino acid derivatives KANEKA CORPORATION (JP) 2006-09-19 US disclosed
US-20050143586-A1 Process for producing optically active amino acid derivatives KANEKA CORPORATION (JP) 2005-06-30 US disclosed
US-6720449-B2 N-PROTECTING AN OPTICALLY ACTIVE 3-HALOALANINE DERIVATIVE FOLLOWED BY CYCLIZATION FOR AZIRIDINE-2-CARBOXYLIC ACID DERIVATIVES KANEKA CORPORATION (JP) 2004-04-13 US disclosed
US-20030032814-A1 Process for preparing optically active amino acid derivatives KANEKA CORPORATION (JP) 2003-02-13 US disclosed
EP-1179530-A1 PROCESSES FOR PREPARING OPTICALLY ACTIVE AMINO ACID DERIVATIVES Kaneka Corporation (JP) 2002-02-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143586-A1 Process for producing optically active amino acid derivatives NPEPPS, AAAS, DDC CHRM1 4257/4885CA4 1236/4885FFAR3 1829/4885
US-20030032814-A1 Process for preparing optically active amino acid derivatives NPEPPS, AAAS, DDC CHRM1 4103/4885CA4 1581/4885FFAR3 1931/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.